RESUMEN
Given the limited understanding about pharmacokinetic-pharmacodynamic (PK-PD) determinants of oseltamivir efficacy, data from two phase 2 influenza virus inoculation studies were evaluated. Healthy volunteers in studies 1 and 2 were experimentally infected with influenza A/Texas (the concentration of neuraminidase inhibitor which reduced neuraminidase activity by 50% [IC(50)] = 0.18 nM) or B/Yamagata (IC(50) = 16.76 nM), respectively. In study 1, 80 subjects received 20, 100, or 200 mg of oral oseltamivir twice daily (BID), 200 mg oseltamivir once daily, or placebo for 5 days. In study 2, 60 subjects received 75 or 150 mg of oral oseltamivir BID or placebo for 5 days. Oseltamivir carboxylate (OC) (active metabolite) PK was evaluated using individual PK data and a population PK model to derive individual values for area under the concentration-time curve from 0 to 24 h (AUC(0-24)), minimum concentration of OC in plasma (C(min)), and maximum concentration of OC in plasma (C(max)). Exposure-response relationships were evaluated for continuous (area under composite symptom score curve [AUCSC], area under the viral titer curve, and peak viral titer) and time-to-event (alleviation of composite symptom scores and cessation of viral shedding) efficacy endpoints. Univariable analyses suggested the existence of intuitive and highly statistically significant relationships between OC AUC(0-24 )evaluated as a 3-group variable and AUCSC, time to alleviation of composite symptom scores, and time to cessation of viral shedding. The upper OC AUC(0-24) threshold (~14,000 ng · h/ml) was similar among these endpoints. Multivariable analyses failed to demonstrate the influence of study/strain on efficacy endpoints. These results provide the first demonstration of exposure-response relationships for efficacy for oseltamivir against influenza and suggest that OC exposures beyond those achieved with the approved oseltamivir dosing regimen will provide enhanced efficacy. The clinical applicability of these observations requires further investigation.
Asunto(s)
Antivirales/farmacología , Antivirales/farmacocinética , Gripe Humana/tratamiento farmacológico , Oseltamivir/análogos & derivados , Adulto , Antivirales/administración & dosificación , Área Bajo la Curva , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Humanos , Subtipo H1N1 del Virus de la Influenza A/enzimología , Virus de la Influenza B/enzimología , Masculino , Análisis Multivariante , Neuraminidasa/antagonistas & inhibidores , Oseltamivir/administración & dosificación , Oseltamivir/farmacocinética , Oseltamivir/farmacología , Factores de Tiempo , Resultado del Tratamiento , Carga Viral , Esparcimiento de Virus , Adulto JovenRESUMEN
AIM: Clopidogrel is metabolized primarily into an inactive carboxyl metabolite (clopidogrel-IM) or to a lesser extent an active thiol metabolite. A population pharmacokinetic (PK) model was developed using NONMEM(®) to describe the time course of clopidogrel-IM in plasma and to design a sparse-sampling strategy to predict clopidogrel-IM exposures for use in characterizing anti-platelet activity. METHODS: Serial blood samples from 76 healthy Jordanian subjects administered a single 75 mg oral dose of clopidogrel were collected and assayed for clopidogrel-IM using reverse phase high performance liquid chromatography. A two-compartment (2-CMT) PK model with first-order absorption and elimination plus an absorption lag-time was evaluated, as well as a variation of this model designed to mimic enterohepatic recycling (EHC). Optimal PK sampling strategies (OSS) were determined using WinPOPT based upon collection of 3-12 post-dose samples. RESULTS: A two-compartment model with EHC provided the best fit and reduced bias in C(max) (median prediction error (PE%) of 9.58% versus 12.2%) relative to the basic two-compartment model, AUC(0-24) was similar for both models (median PE% = 1.39%). The OSS for fitting the two-compartment model with EHC required the collection of seven samples (0.25, 1, 2, 4, 5, 6 and 12 h). Reasonably unbiased and precise exposures were obtained when re-fitting this model to a reduced dataset considering only these sampling times. CONCLUSIONS: A two-compartment model considering EHC best characterized the time course of clopidogrel-IM in plasma. Use of the suggested OSS will allow for the collection of fewer PK samples when assessing clopidogrel-IM exposures.
Asunto(s)
Modelos Biológicos , Inhibidores de Agregación Plaquetaria/farmacocinética , Ticlopidina/análogos & derivados , Administración Oral , Adolescente , Adulto , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Cromatografía de Fase Inversa , Clopidogrel , Humanos , Jordania , Masculino , Persona de Mediana Edad , Ticlopidina/farmacocinética , Factores de Tiempo , Adulto JovenAsunto(s)
Psicoterapia , Cuidado Terminal/psicología , Muerte , Miedo , Femenino , Humanos , Japón , MasculinoRESUMEN
Morita psychotherapy, a form of therapy developed in Japan some sixty years ago, has survived extensive changes in Japanese society, and is now enjoying popularity in the United States. This gives us an opportunity to look closely at the concept of 'cultural fit' between an important therapeutic technique and its social milieu, and to speculate about recent changes in American culture that may account for the growing popularity of Moritism. In contrast to Western style 'talking therapies' like psychoanalysis, Morita psychotherapy is relatively group-centered, ritualistic, and behavioristic. On would expect to find these features in a Japanese therapy, but their acceptance in America suggests that previously popular Western techniques may not be optimum for handling certain problems of the post-industrial American. McLuhan, Peacock, Douglas, and others have suggested some emerging traits of Western character that might shed some light on this question.